Ready-to-use viral vectors for gene delivery

Amsbio now offers a ready-to-use range of lentiviral particles designed to deliver target genes into virtually any mammalian cell type, both dividing and non-dividing, in vitro and in vivo. These high-titre, pre-made viral vectors make it possible to achieve long-term, stable gene expression without the usual bottlenecks of transfection or vector production.

Researchers can use these particles for applications ranging from stable cell line engineering and CRISPR gene editing to CAR-T cell development and therapeutic gene transfer. With titres exceeding 1×10⁷ IFU/mL and a third-generation self-inactivating (SIN) vector system, the particles are efficient, safe, and BSL-2 compatible. Using pre-made particles can save up to four weeks of laboratory work, letting teams focus on discovery rather than logistics.

The impact of these tools is already being seen in published research. In a recent study, US scientists used Amsbio lentiviral particles to explore how the RNA-binding protein HuR regulates CCL2 expression, shedding light on mechanisms that may influence chronic inflammatory conditions like HIV-associated neurocognitive disorder and atherosclerosis.

To read the study in full please click here.

From research-grade experiments to GMP-grade clinical applications, Amsbio’s lentiviral particles offer a versatile, time-saving solution for modern molecular biology and therapeutic research.

More information online